Retatrutide Phase 3 data is out and the numbers are proper wild

Posted by peptidehead914 in Weight Loss & Metabolic - 1 points, 0 comments.

https://www.biopharmadive.com/news/lillys-retatrutide-tripleG-phase3-obesity-data/820851

So Lilly's triple-acting obesity drug retatrutide just hit its Phase 3 endpoint and the weight loss numbers are apparently bariatric-surgery level, which is basically the kind of result that makes you sit up and pay attention. It is a triple agonist hitting GLP-1, GIP, and glucagon receptors, so it is doing more than semaglutide or tirzepatide under the hood.

I am cautiously excited but also a bit annoyed at how these press releases always frame things. They never give you the actual percentage weight loss front and centre, you have to dig for it, and they conveniently skip over the side effect profile which for a triple agonist is going to be the real question mark. My own experience with GLP-1 compounds is that the appetite suppression is real but the fatigue and GI stuff can be rough, and adding glucagon receptor agonism on top of that is basically asking your liver and gut to do extra work they might not thank you for.

Anyone here been following the glucagon receptor angle specifically? I am curious whether the thermogenic effect from glucagon actually shows up meaningfully in real-world data or if it is just a nice mechanistic talking point.

Community discussion - research and educational context only. Not medical advice.